Dual Targeting Strategies in Cancer: Carbonic Anhydrase IX Inhibitors Targeting EGFR or VEGFR-2

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Tumor microenvironment, particularly hypoxia, drives tumorigenesis and impacts prognosis.
• Carbonic anhydrases (CAs), especially CA IX, are overexpressed in cancers under hypoxic and acidic conditions, promoting tumor progression.
• Vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) are critical in angiogenesis and cancer cell proliferation.

Purpose of the Study:

• To review novel compounds designed to inhibit CA IX.
• To explore dual-targeting strategies involving CA IX inhibition combined with VEGFR-2 or EGFR blockade.
• To highlight the potential of multifunctional drugs in cancer therapy.

Main Methods:

• Literature review of recent studies on novel anticancer compounds.
• Analysis of compounds targeting CA IX, VEGFR-2, and EGFR pathways.
• Focus on the development of multifunctional agents.

Main Results:

• CA IX inhibition is linked to reduced cancer cell proliferation, migration, and invasion.
• Blocking VEGFR-2 signaling is a key strategy to inhibit tumor angiogenesis and growth.
• EGFR plays a significant role in the progression of various cancers, including brain and lung cancers.

Conclusions:

• Multifunctional drugs targeting multiple pathways offer a promising therapeutic approach for cancer.
• Novel compounds inhibiting CA IX and simultaneously targeting VEGFR-2 or EGFR present a strategy to enhance therapeutic effectiveness and reduce side effects.
• Further development of these agents is crucial for advancing cancer treatment.